Ratsional'naya farmakoterapiya SD 2 tipa: primenenie ingibitora DPP-4 saksagliptina i metformina v klinicheskoy praktike


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

It is known that an adequate glycemic control reduces the incidence and progression of complications associated with type 2 diabetes mellitus (DM2). However, at least half of the DM2 patients fail to achieve target levels of blood glucose, which is often associated with inefficiency of traditionally prescribed drugs in the maintenance of β-cell function. Therefore, effective management of DM2 requires new approaches to therapy and the search for new classes of drugs and their combinations. Clinical trials of drug saxagliptin, a representative of new class gliptins, showed not only its efficacy in reducing blood glucose levels and improving the function of β-cells, but also a low risk of hypoglycemia, no increase in the cardiovascular risk, a neutral effect on body weight; therefore, saxagliptin can be used as monotherapy or in combination with other oral antihyperglycemic drug or insulin, depending on the initial level of glycated hemoglobin. Currently, combination of metformin and gliptin is recognized as the most optimal combination for the treatment of DM2. Advantage of combination of saxagliptin and metformin is related to with complementary action of drugs, efficacy in all parameters of glycemic control, safety, including lower risk of hypoglycemia, lack of negative effect on body weight and cardiovascular risk.

Full Text

Restricted Access

About the authors

A. S Ametov

A. V Brashchenkova

References

  1. Дедов И.И., Шестакова М.В. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 5-й вып. // Сахарный диабет 2011. № 3 (прил.).
  2. Rodbard H.W., Jellinger P.S., Davidson J.A., et al. Statement by an American Association of clinical endocrinologists/ American college of endocrinology consensus panel on Type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59.
  3. Inzucchi S.E., et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55(6): 1577-96.
  4. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
  5. Centers for Disease Control and Prevention: National Diabetes Fact Sheet, 2007. Available at http://www.cdc.gov/diabetes/pubs/pdf/ ndfs_2007.pdf. Accessed September 2010.
  6. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet 2006;368:
  7. Gallwitz B. GLP-1 agonists and dipeptidylpeptidase IV inhibitors. Handb. Exp Pharmacol 2011;203:53-74.
  8. Scheen A.J. A review of gliptins in 2011. Exp Opin Pharmacother 2012;13:81-99.
  9. Hollander P.A., Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med 2010;122:71-80.
  10. Ahren B., Foley J.E., Bosi E. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011;13:193-203.
  11. Derosa G., Maffioli P Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of Type 2 diabetes. Diabetes Metab Syndr Obes 2011;4:263-71.
  12. Neumiller J.J., Campbell R.K. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of Type 2 diabetes mellitus. Am J Health Syst Pharm 2010;67:1515-25.
  13. Dhillon S., Weber J. Saxagliptin. Drugs 2009;69:2103-14.
  14. Kania D.S., Gonzalvo J.D., Weber Z.A. Saxagliptin: a clinical review in the treatment of Type 2 diabetes mellitus. Clin Ther 2011;33:1005-22.
  15. Stumvoll M., Nurjhan N., Perriello G., et al. Metabolic effects of metformin in non-insulindependent diabetes mellitus. N Engl J Med 1995;333:550-54.
  16. Hundal R.S., Inzucchi S.E. Metformin: new understandings, new uses. Drugs 2003; 63:1879-94.
  17. Setter S.M., Iltz J.L., Thams J., et al. Metformin hydrochloride in the treatment of Type
  18. diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther 2003;25: 2991-3026.
  19. Consoli A., Gomis R., Halimi S., et al. Initiating oral glucose-lowering therapy with metformin in Type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 2004;30:509-16.
  20. Anfossi G., Russo I., Bonomo K., et al. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of Type 2 diabetes mellitus. Curr Vasc Pharmacol 2010;8:327-37.
  21. Messaoudi S.E., Rongen G.A., de Boer R.A., et al. The cardioprotective effects of metformin. Curr Opin Lipidol 2011;22:445-53.
  22. Decensi A., Puntoni M., Goodwin P., et al. Metformin and cancer risk in diabetic patients: a systematic review and meta- analysis. Cancer Prev Res (Phila.) 2010;3:1451-61.
  23. Krentz A.J., Patel M.B., Bailey C.J. New drugs for Type 2 diabetes mellitus: what is their place in therapy? Drugs 2008;68:2131-62.
  24. Henry R.R., Smith S.R., Schwartz S.L., et al. Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with Type 2 diabetes. Diabetes Obes. Metab 2011;13:850-8.
  25. Frederich R., Alexander J.H., Fiedorek F.T., et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for Type 2 diabetes. Postgrad Med 2010;122:16-27.
  26. Migoya E.M., Bergeron R, Miller JL, et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010;88:801-8.
  27. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycaemia in Type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30.
  28. Bailey C.J., Wilcock C., Scarpello J.H. Metformin and the intestine. Diabetologia. 2008; 51(8):1552-379.
  29. Dandona P., Fonseca I., Mier A., Beckett A.G. Diarrhea and metformin in a diabetic clinic. Diabetes Care 1983;6(5):472-4.
  30. Rosenstock J., Sankoh S., List J.F. Glucoselowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008;10 (5):376-86.
  31. Инструкция по медицинскому применению лекарственного препарата Онглиза (таблетки, покрытые оболочкой, 2,5 мг, 5 мг). Регистрационное удостоверение ЛСР 08697/10 (изменение №1) от 30.03.2012.
  32. Monnier L., Lapinski H., Collette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of Type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003;26:881-85.
  33. Maheux P., et al. Efficacy and Safety of Saxagliptin 5 mg Once-Daily Therapy in Elderly Patients with Type 2 Diabetes Mellitus. Diabetologia 2009;52(1):302.
  34. Patel C.G., Kornhauser D., Vachharajani N., et al. Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. Diabetes Obes Metab 2011; 13:604-14.
  35. DeFronzo R.A., Hissa M.N., Garber A.J., et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled Type 2 diabetes with metformin alone. DiabetesCare 2009;32:1649-55.
  36. DeFronzo R., Hissa M., Garber A., et al. Oncedaily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with T2D. Diabetes 2009;58: abstr.547.
  37. Hermans M.P., Delibasi T., Farmer I., et at. Effects of saxagliptin added to sub- maximal doses of metformin compared with dose escalation of metformin in Type 2 diabetes: results from the PROMPT study. Diabetologia 2011;54 (1):828.
  38. Goke B., Gallwitz B., Eriksson J., et al. Saxagliptin vs glipizide as add-on to metformin for Type 2 diabetes mellitus (T2DM): long-term safety and efficacy. Diabetes 2011;60(1):abstr.1110.
  39. Rao A., et al. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? Diabetes Care 2008;31:1672-78.
  40. Chacra A.R., Tan G.H., Apanovitch A., et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonyl-urea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009;63(9):1395-406.
  41. Jadzinsky M., Pfutzner A., Paz-Pacheco E., et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with Type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11:611-22.
  42. Pfutzner A., Paz-Pacheco E., Allen E., et al. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab 2011;13:567-76.
  43. Charbonnel B., Barnett A.H., Donovan M., et al. Saxagliptin (SAXA) add-on therapy improves glycemic control in patients (pts) with poorly controlled Type 2 diabetes (T2D) on insulin (INS) alone or INS combined with metformin (MET). Diabetes 2011;60(1):abstr.1108.
  44. Barnett A.H., Charbonnel B., Li J., et al. Saxagliptin add-on therapy to insulin with or without metformin for Type 2 diabetes mellitus: 52-week safety and efficacy. Diabetologia 2011;54(1):243.
  45. Senior PA. Type 2 diabetes, metformin and lactic acidosis-defining the risk and promoting safe practice. Diabet Med 2011;29(2):161-63.
  46. Butler P.C., Matveyenko A.V., Dry S., et al. Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? Diabetologia 2010;53:1-6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies